Suppr超能文献

免疫抑制剂在儿科器官移植中的发育药理学。

Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.

机构信息

Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center (CIC) Inserm 9202, Hôpital Robert Debré, Paris, France.

出版信息

Ther Drug Monit. 2010 Dec;32(6):688-99. doi: 10.1097/FTD.0b013e3181f6502d.

Abstract

Cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil are the primary immunosuppressants used on pediatric organ transplantation. Therapeutic drug monitoring is used in daily practice, because their clinical use is hampered by a narrow therapeutic index and large variability. Tailoring immunosuppressive therapy to the individual patient to optimize efficacy and minimize toxicity is therefore essential. Because research in pharmacogenetics already identified polymorphisms impacting their pharmacokinetic parameters in adults, developmental pharmacogenetics of immunosuppressants holds promises for optimizing dosage regimens and improving clinical outcome in children. In this review, we focus on the impact of age and pharmacogenetics on these immunosuppressants in children undergoing organ transplantation.

摘要

环孢素、他克莫司、西罗莫司和霉酚酸酯是儿科器官移植中主要使用的免疫抑制剂。由于其治疗指数较窄且变异性较大,因此在日常实践中使用治疗药物监测。因此,将免疫抑制治疗个体化以优化疗效并最小化毒性至关重要。由于药物遗传学研究已经确定了影响成人药代动力学参数的多态性,因此免疫抑制剂的发展药物遗传学有望优化儿童器官移植患者的剂量方案并改善临床结局。在这篇综述中,我们重点讨论了年龄和药物遗传学对这些免疫抑制剂在接受器官移植的儿童中的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验